Table 3.

1st treatment regimen initiated in the past 12 months, as a function of the ECOG score, patient age and location of metastases

	TOTAL	Age			ECOG		Location of metastases
		< 60 yrs	60–70 yrs	> 70 yrs	0–1	2–4	B	V ± B	C±
	N = 1648 (%)	N = 770 (%)	N = 509 (%)	N = 369 (%)	N = 1335 (%)	N = 304 (%)	N = 855 (%)	N = 1298 (%)	N = 160 (%)
CT and TT and no HT	75	83*	81	51**	78*	62	69**	81*	76
Docetaxel+trastuzumab+pertuzumab	36	47*	40	12**	41*	17	35	39	28**
Paclitaxel+trastuzumab	9	7	11	9	8	12	9	9	11
Paclitaxel+trastuzumab+pertuzumab	9	10	8	6	10*	3	7	9	7
Docetaxel+trastuzumab	6	6	6	5	6	6	5	7	9
Vinorelbine+trastuzumab	4	2	2	7*	3	6*	4	4	3
Capecitabine+trastuzumab	3	2	2	8*	2	8*	3	4	5
Capecitabine+lapatinib	2	2	2	1	2	3	2	2	6*
Docetaxel+pertuzumab	1	1	2	1	1	1	< 1**	2	2
HT and TT and no CT	13	6**	9**	33*	12	17*	20*	8**	9**
Trastuzumab+non-steroidal AI	9	3**	6**	26*	8	13*	14*	6**	5**
Lapatinib+non-steroidal AI	2	1	1	4*	2	2	3*	1**	1
Trastuzumab+steroidal AI	1	< 1	1	1	1	1	1	< 1	1
TT only	6	7	7	6	6	7	6	6	9
T-DM1	3	3	3	1	3	2	1	3	6*
Trastuzumab+pertuzumab	2	3	2	< 1**	2	1	2	2
Trastuzumab	2	1	1	4*	1	4*	3	1	3
CT only	4	3	4	6	2	10*	4	4	6
CT and TT and HT	1	1	< 1	1	1	1	< 1	1	1
HT only	1	1		2*	< 1	3*	1	< 1
CT and HT and no TT	< 1			1	< 1		< 1	< 1

B bone, V ± B visceral ± bone, C ± , cerebral ± others, CT chemotherapy, TT targeted therapy, HT hormonotherapy, AI aromatase inhibitors

* Value is significantly higher than the comparator group

** Value is significantly lower than the comparator group